Related Experiment Video
Updated: Aug 16, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
EFFECTIVENESS OF PLASMA EXCHANGE IN THE THERAPY OF DRUG-INDUCED HEPATITIS IN PATIENTS WITH PULMONARY TUBERCULOSIS AND
K Kurmangaliyeva1, R Shlymova2, K Askarova2
11City Center of Phthisiology and Internal Diseases, Astana, Kazakhstan; 2Astana Medical University, Kazakhstan.
Background:
This study evaluated the effectiveness of plasma exchange for the management of drug-induced hepatitis in patients with drug-resistant pulmonary tuberculosis, including those with concomitant chronic viral hepatitis. Along with standard conservative therapy, increasing attention is being paid to extracorporeal hemocorrection methods in the treatment of acute hepatitis.
Materials And Methods:
The study included 127 patients with drug-resistant pulmonary tuberculosis treated at the City Center for Phthisiology and Internal Medicine in Astana from 2024 to February 2026. Chronic viral hepatitis was diagnosed in 65 of 127 patients: hepatitis B in 9 (13.8%), hepatitis C in 51 (78.5%), and mixed hepatitis B + C in 5 (7.7%). During anti-tuberculosis chemotherapy, 53 of 127 patients (41.7%) developed drug-induced hepatitis. This complication occurred significantly more often in patients with chronic viral hepatitis than in those without it: 39 of 65 (60.0%) versus 14 of 62 (22.6%), respectively (p < 0.001). Patients were divided into two groups, one of which received plasma exchange for the correction of drug-induced hepatitis.
Results:
The use of plasma exchange in the study group made it possible to control manifestations of drug-induced hepatitis without discontinuing specific anti-tuberculosis therapy. In the control group, where plasma exchange was not used, temporary interruption of specific therapy was required.
Conclusion:
The inclusion of plasma exchange in the comprehensive treatment of drug-induced hepatitis in patients with drug-resistant pulmonary tuberculosis made it possible to control hepatotoxicity without interrupting anti-tuberculosis chemotherapy, which is especially important in patients with concomitant chronic viral hepatitis.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:25Hepatitis
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...